| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... New England Journal of Medicine 359 (9), 906-917, 2008 | 2455 | 2008 |
| High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma T Philip, JO Armitage, G Spitzer, F Chauvin, S Jagannath, JY Cahn, ... New England Journal of Medicine 316 (24), 1493-1498, 1987 | 913 | 1987 |
| Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in … MV Mateos, PG Richardson, R Schlag, NK Khuageva, MA Dimopoulos, ... Journal of Clinical Oncology 28 (13), 2259-2266, 2010 | 567 | 2010 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group C Fernández de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, ... Leukemia 27 (4), 780-791, 2013 | 410 | 2013 |
| International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, ... The lancet oncology 20 (6), e302-e312, 2019 | 378 | 2019 |
| Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma LF Verdonck, WLJ van Putten, A Hagenbeek, HC Schouten, P Sonneveld, ... New England Journal of Medicine 332 (16), 1045-1051, 1995 | 371 | 1995 |
| New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ... Leukemia 28 (3), 525-542, 2014 | 304 | 2014 |
| VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results … MA Dimopoulos, PG Richardson, R Schlag, NK Khuageva, O Shpilberg, ... Journal of Clinical Oncology 27 (36), 6086-6093, 2009 | 210 | 2009 |
| Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation R Schots, L Kaufman, I Van Riet, T Ben Othman, M De Waele, ... Leukemia 17 (6), 1150-1156, 2003 | 191 | 2003 |
| A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation S Verheyden, R Schots, W Duquet, C Demanet Leukemia 19 (8), 1446-1451, 2005 | 181 | 2005 |
| Ethical considerations on preimplantation genetic diagnosis for HLA typing to match a future child as a donor of haematopoietic stem cells to a sibling G Pennings, R Schots, I Liebaers Human Reproduction 17 (3), 534-538, 2002 | 180 | 2002 |
| A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology JP Cazenave, G Follea, L Bardiaux, JM Boiron, B Lafeuillade, M Debost, ... Transfusion 50 (11), 2362-2375, 2010 | 171 | 2010 |
| Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma … R Pettengell, N Schmitz, C Gisselbrecht, G Smith, WN Patton, B Metzner, ... Journal of clinical oncology 31 (13), 1624-1630, 2013 | 137 | 2013 |
| The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. R Schots, I Van Riet, S Damiaens, J Flament, P Lacor, Y Staelens, ... Bone marrow transplantation 17 (4), 509-515, 1996 | 137 | 1996 |
| Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts S Faict, J Muller, K De Veirman, E De Bruyne, K Maes, L Vrancken, ... Blood cancer journal 8 (11), 105, 2018 | 135 | 2018 |
| Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells I Van Riet, MD Waele, L Remels, P Lacor, R Schots, BV Camp British journal of haematology 79 (3), 421-427, 1991 | 123 | 1991 |
| Novel universal approach for preimplantation genetic diagnosis of β‐thalassaemia in combination with HLA matching of embryos H Van de Velde, I Georgiou, M De Rycke, R Schots, K Sermon, W Lissens, ... Human Reproduction 19 (3), 700-708, 2004 | 122 | 2004 |
| Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma … T Facon, JL Harousseau, F Maloisel, M Attal, J Odriozola, A Alegre, ... Blood, The Journal of the American Society of Hematology 94 (4), 1218-1225, 1999 | 119 | 1999 |
| Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival I Van de Broek, X Leleu, R Schots, T Facon, K Vanderkerken, ... haematologica 91 (2), 200-206, 2006 | 107 | 2006 |
